

RECEIVED


JUN 19 2001

TECH CENTER 1600/2900

PATENT

Application Serial No. 09/512,701

Attorney Docket No. 01142.0147-01



In the Claims:

Please amend claims 17-20 as follows:

17. (Amended) The method of claim 16, wherein said antagonist is administered in a dose of about 0.05 to about 25 mg/kg.

18. (Amended) The method of claim 16, wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

B2 19. (Amended) The method of claim 16, wherein said antagonist is an antibody immunoreactive with IL-12.

20. (Amended) The method of claim 16, wherein said antagonist is an antibody fragment immunoreactive with IL-12.

REMARKS

Formal Matters

Claims 16-20 are pending in this application, and the Examiner has rejected all of the claims. Applicants confirm that their undersigned representative elected Group II, claims 16-20, in a telephone interview with the Examiner.

Applicants have made minor amendments to claims 17-20 to correct inadvertent typographical errors. These amendments are not intended to affect the scope of the claims in any way.

The Examiner has not yet acknowledged Applicants claim to priority. Applicants request that the Examiner acknowledge the claim to priority to U.S. Ser. No.

08/212,629, filed March 14, 1994. The Examiner has also asked that Applicants update

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000